Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015; Gland Pharma has informed that it enclosed the Investor Presentation on Q1FY23 Financial Results.
The above information is a part of company’s filings submitted to BSE.